Rocket Pharmaceuticals is trading at $2.67, up 5.13%, after Goldman Sachs upgraded its rating from Sell to Neutral and raised its price target from $3 to $4, citing updated RP-A501 gene-therapy data for Danon disease.
- The clinical update included long-term Phase 1 findings and preliminary results from the first four Phase 2 patients.
- Goldman’s report explicitly linked the premarket gain to the upgrade; the broader biotech sector was down, making company-specific news the clearer catalyst.